• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF- α-mediated apoptosis of cancer cells
Biochem Pharmacol. 2021 Dec 2:114865. doi: 10.1016/j.bcp.2021.114865. Online ahead of print.ABSTRACTPrevious studies have confirmed that docetaxel (DTX) treatment increases TNF-α production in cancer cells, but its mechanism of action remains unclear. Therefore, this study aimed to determine the signaling axis by which DTX induced the expression of TNF-α in U937 leukemia and MCF-7 breast carcinoma cells. DTX treatment promoted Ca2+-controlled autophagy and SIDT2 expression, resulting in lysosomal degradation of miR-25 in U937 cells. Downregulation of miR-25 increased NOX4 mRNA stability and protein expression. NOX4-stimu...
Source: Biochemical Pharmacology - December 5, 2021 Category: Drugs & Pharmacology Authors: Liang-Jun Wang Jing-Ting Chiou Yuan-Chin Lee Long-Sen Chang Source Type: research

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Conclusions MDSC are major players in the immunosuppressive scenario in cancer, thanks to their phenotype heterogeneity and critical interaction with several innate immune cells, thus representing a crucial target in oncology. Here we reviewed the interactions of MDSCs with NK cells. The contribution of key cytokines, chemokines and mediators active in this process have been discussed. We also described the contribution of MDSC on angiogenesis directly or indirectly through interactions with NK and immunosuppressive activities. A parallel of the cancer associated to the decidual counterpart of these cells is discussed, a...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in  vivo.
CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo. Mol Med Rep. 2017 Jun 07;: Authors: Liu T, Wu X, Wang Y, Hou X, Jiang G, Wu T, Xie H, Xie M Abstract The co-delivery of a drug and a target gene has become a primary strategy in cancer therapy. Based on our previous study, a synthesized star‑shaped co‑polymer consisting of β‑cyclodextrin (CD) and a poly(L‑lysine) dendron (PLLD) was used to co-deliver docetaxel (DOC) and matrix metalloproteinase 9 (MMP‑9) small interfering RNA, via CD‑PLLD/DOC/MMP‑9 complexes, into mice implanted with HN...
Source: Molecular Medicine Reports - October 29, 2017 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Livin enhances chemoresistance in head and neck squamous cell carcinoma.
In conclusion, our results suggest that siRNA-mediated Livin knockdown enhanced the chemosensitivity of the three HNSCC cell lines to cisplatin, 5-FU and docetaxel. Although further investigations are required to support these findings, our results demonstrated that novel therapeutic strategies with combined use of siRNA targeting Livin and chemotherapeutic agents may have applications in the treatment of advanced HNSCC. PMID: 28440463 [PubMed - as supplied by publisher]
Source: Oncology Reports - April 27, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

ABCB1 Is Upregulated in Acquisition of Taxane Resistance: Lessons from Esophageal Squamous Cell Carcinoma Cell Lines.
In conclusion, we propose that ABCB1 might play a pivotal role in acquisition of taxane resistance and could be a promising target for treatment of patients with esophageal cancer after acquisition of taxane resistance. PMID: 27941276 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - December 14, 2016 Category: Research Authors: Wang R, Sumarpo A, Saiki Y, Chen N, Sunamura M, Horii A Tags: Tohoku J Exp Med Source Type: research

Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy.
Authors: Liu T, Wu X, Wang Y, Zhang T, Wu T, Liu F, Wang W, Jiang G, Xie M Abstract The co-delivery of drug and gene has become the primary strategy in cancer therapy. Based on our previous work, to co-deliver docetaxel (DOC) and MMP-9 siRNA more efficiently for HNE-1 nasopharyngeal carcinoma therapy, a folate-modified star-shaped copolymer (FA-CD-PLLD) consisting of β-cyclodextrin (CD) and poly(L-lysine) dendron (PLLD) was synthesized, and then used for DOC and MMP-9 co-delivery. Different from commonly used amphiphilic copolymers micelles, the obtained CD derivative could be used directly for the combinatorial d...
Source: Oncotarget - June 5, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract 1724: Integrated functional RNAi screening and structural genomics identify inverse co-modulators of TP53 family and NF-{kappa}B transitional activation as potential therapeutic targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide with a 50-60% mortality rate. Deregulation of p53 family members in HNSCC occurs in over 90% of cases, preventing transcription of growth arrest and apoptosis genes. Conversely, members of the NF-κB/REL family are aberrantly activated in about ∼70% of cases, and drive expression of pro-proliferation, inflammation, angiogenesis, and therapeutic resistance genes. The function of different TP53 and NF-κB family members are inversely modulated within two major subsets of HNSCC, suggesting that common molecules and pathways coordinate this...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saleh, A., Cornelius, S., Martin, S., Ormanoglu, P., Cheng, H., Das, R., Yang, X., Chen, Z., Van Waes, C. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 2623: PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human head and neck squamous cell carcinoma
In this study, we determined the effects of the novel PI3K-mTOR inhibitor PF-5212384 (PF-384) on molecular targets and HNSCC growth in preclinical models. PF-384 IC50s of 0.75nM-133nM were found in 12 HNSCC lines by XTT cell density assays and treatment resulted in increased sub-G0 cell death and G0/G1 phase blockade by DNA flow cytometry. PF-384 strongly inhibited direct targets of PI3K-mTOR, aberrant NF-kB transactivation and induced cytokines, but only partially inhibited MEK pathway targets. Transient siRNA knockdown of PIK3CA inhibited NF-kB activity, supporting PI3K-mTOR as an important driver and target for inhibiti...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Mohan, S., Broek, R. J. V., Saleh, A. D., Pierce, M. L., Coupar, J. F., Eytan, D. F., Chen, Z., Waes, C. V. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 5033: Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell
Conclusions: The findings obtained from the current study suggested that 5-FU and DTX may enhance the T cell-stimulating ability of DCs via down-regulation of PD-L1 and PD-L2 mediated by STAT3 inhibition, and that the combination therapy of DC-based cancer vaccine with these anti-cancer drugs may elicit better anti-tumor immune response than only vaccination. Citation Format: Masato Okamoto, Tomoyuki Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki Hamakawa. Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell. [abst...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, M., Tano, T., Goda, H., Fujita, Y., Nakashiro, K.-i., Hamakawa, H. Tags: Immunology Source Type: research

Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma
Highlights: ► HORMAD1 is a cancer/testis antigen expressed exclusively in germ cells during normal development. ► HORMAD1 is expressed in a substantial portion of human epithelial ovarian cancers. ► HORMAD1 down-regulation affected tumor growth in mouse models of human ovarian cancer.Abstract: The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invas...
Source: Cancer Letters - July 30, 2012 Category: Cancer & Oncology Authors: Mian M.K. Shahzad, Yong-Hyun Shin, Koji Matsuo, Chunhua Lu, Masato Nishimura, De-Yo Shen, Yu Kang, Wei Hu, Edna M. Mora, Cristian Rodriguez-Aguayo, Arvinder Kapur, Justin Bottsford-Miller, Gabriel Lopez-Berestein, Aleksandar Rajkovic, Anil K. Sood Tags: Mini-reviews Source Type: research